In today's rapidly evolving healthcare landscape, the traditional models of delivering and accessing healthcare innovations are being challenged. The European Union regulation for Health Technology Assessment (HTAR) is going through significant changes in the coming years, leading to a new era for evaluating the effectiveness, safety, and value of healthcare technologies. Value-Based Healthcare offers a transformative approach, emphasizing on building partnerships between different healthcare stakeholders to improve patient outcomes and the value received from treatments rather than just the volume of services provided.

In this webinar, we delve into how VBHC principles can revolutionize the pharmaceutical industry, particularly in terms of enhancing patient access to innovative therapies. VBHC initiatives support aligning incentives on patient outcomes and foster collaborations with the healthcare stakeholders and pharmaceutical industry. These partnerships are valuable as they have a joint focus on proving treatments that truly benefit patients, and thereby lead to improved health outcomes and a more sustainable healthcare system.

Throughout the webinar, we will explore the key components of VBHC, its implementation challenges, and the opportunities it presents for pharmaceutical companies to drive innovation access while ensuring treatment outcomes and quality of care. We will also discuss real-world examples of successful VBHC initiatives, partnerships between healthcare practitioners and the pharmaceutical industry and strategies for overcoming barriers to adoption.